Misinterpretation of TPMT by a DTC genetic testing company

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 598-600

  Brownstein, C A ^a   Margulies, D M ^a   Manzi, S F ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ALLELE; ARTICLE; ASHKENAZI JEW; BREAST CANCER; CAUCASIAN; CROHN DISEASE; DISEASE COURSE; ENZYME ACTIVITY; GENE FREQUENCY; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HUMAN; INFORMED CONSENT; LEUKEMIA; PHARMACOGENETICS; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; REASSURANCE; SINGLE NUCLEOTIDE POLYMORPHISM; TURNAROUND TIME;

ALLELES; BREAST NEOPLASMS; GENETIC TESTING; METHYLTRANSFERASES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84901194062     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.60     Document Type: Article

References (5)

1. Eriksson, N. et al. Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet. 6, e1000993 (2010
2. Evans, W.E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther. Drug Monit. 26, 186-191 (2004
3. Relling, M.V. et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93, 324-325 (2013
4. Ball, M.P. et al. A public resource facilitating clinical use of genomes. Proc. Natl. Acad. Sci. USA. 109, 11920-11927 (2012
5. Hall, M.J. et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115, 2222-2233 (2009